CJC-1295: One 2006 Study, Eighteen Years of Weekly Use

One study. One human study, in eighteen years, on the peptide that longevity clinics are injecting into people every week. Published in 2006. And in the time since, nobody has run a trial asking whether the hormone numbers it produces actually change body composition, recovery, or anything else a person taking it might care about.

That’s not a knock on the molecule. The pharmacology is real, and we’ll get into exactly how real. The mismatch is between how long CJC-1295 has been in clinical use and how thin the file behind it actually is. Two studies. Same year. Same journal issue, more or less. That’s the whole record.

Here’s the specific problem, and it’s worth holding onto before we go further: the feature that made CJC-1295 clinically convenient, a once-weekly shot instead of a daily one, is also the feature that makes the hormone signal it produces hardest to read. Keep that in mind. We’ll come back to it.

The chemical tag that made it weekly

CJC-1295 is a modified version of a hormone your body already makes: growth hormone-releasing hormone (GHRH), the signal that tells the pituitary gland to release growth hormone. The modification is a chemical tag stitched onto one end of the molecule that latches onto a protein called albumin, which is always floating around in your blood. Once that tag grabs onto albumin, the molecule stops clearing out of your system in minutes and instead hangs around for roughly eight days (C6). A drug that used to be gone in twenty minutes is now still active in your bloodstream a week later.

That’s not a minor tweak. That is the entire reason this peptide exists as a commercial product. One shot instead of seven. Compliance problem solved.

Chemically, this version of the molecule is sometimes described as a modified 29-amino-acid GHRH fragment carrying that albumin-binding chemical tag on its tail end (C7). You don’t need the chemistry name to understand what matters: it sticks to a blood protein, and sticking to that protein is what buys it the extra week.

The human data on what that week actually does exists, and it’s not nothing. Teichman and colleagues ran an absorption-and-clearance study in 2006, in healthy adults aged 21 to 61, testing single doses (C1). Growth hormone went up 2-to-10-fold above baseline and stayed elevated for up to six days. IGF-1, the downstream hormone GH triggers the liver to produce, went up 1.5-to-3-fold (C2). The molecule does what it says on the label. That part is confirmed, and confirmed well: this is a real, measured pharmacological effect, not a rumor from a forum.

But a study measuring how fast a molecule enters and clears your body tells you the molecule is active. It does not tell you what that activity is doing to your muscles, your bones, or your longevity ten years from now.

Does the hormone still pulse, or does it just stay on?

Growth hormone doesn’t sit in your blood at a steady level. It comes out in bursts, spikes and quiet stretches, several times a day. That rhythm isn’t decoration. The tissues that respond to GH are tuned to that on-off pattern; a steady drip of the hormone is a different biological signal than a burst, even if the total amount released over a day works out the same.

So when CJC-1295 landed, with a version of GHRH that doesn’t leave your bloodstream for over a week, the obvious question was whether it would just jam the signal on. Does the pituitary keep bursting, or does it flatten into one long continuous release?

Ionescu and Frohman answered that directly, also in 2006 (C4). Their finding: the bursts were still there. Growth hormone kept coming out in a pulsing pattern even with CJC-1295 sitting on albumin in the blood for days at a stretch (C5). The rhythm wasn’t erased.

That finding is the one that closed the argument, or seemed to. Pulse preserved. Worry resolved. Weekly dosing, justified.

Except look closer at what was actually tested. Ionescu and Frohman showed the pattern survives. They did not measure whether the size of those bursts, the spacing between them, and what happens downstream in muscle and bone under a week-long albumin-bound signal match what your body produces when it’s running the show itself, with nothing artificial in the loop. Those are two different questions. One got an answer in 2006. The other one is still sitting there, unanswered, eighteen years later.

The pulse-preserved finding settled a conversation before anyone asked the harder question that actually mattered.

What the full human file actually contains

Here’s every human trial that has ever measured what CJC-1295 does to body composition, recovery, muscle function, or any marker of aging, across months of actual use in people.

None. Zero.

The complete record is one study from 2006 tracking how fast the body absorbs and clears the compound, and one study on the hormone-pulse pattern, also from 2006. Then eighteen years of clinical use with no functional trial in between.

The more recent reviews don’t change that. A 2026 review in the American Journal of Sports Medicine looked at six injectable peptide therapies used in sports medicine and found that CJC-1295 combined with a second peptide called ipamorelin improved muscle strength in mice whose muscles were wasting from steroid exposure (C8). Mice. Not people. No human orthopaedic data exists for that combination at all (C8). A separate 2026 review in Frontiers in Aging covered nine peptides used against aging and drew a clear line between the ones with FDA-approved status backed by large trials, and the ones without it, CJC-1295 among the latter (C9). Neither review adds a single human functional endpoint. A broader 2020-2025 look at injectable peptides for muscle and joint recovery reached the same conclusion from the other direction: the clinical promotion has outpaced the clinical evidence (C10).

Eighteen years of clinics prescribing it, and people self-administering it at home, resting on a study from 2006 and a mechanistic follow-up from the same year. That’s the tier.

This isn’t a gap because the molecule doesn’t work. Nobody has shown that it doesn’t. It’s a gap because nobody, in eighteen years, has run the trial that would tell you what the working molecule actually accomplishes in a person’s body over time.

The convenience feature is the evidence gap

Here’s the thing that neither 2006 study resolved, and that almost two decades of clinical use hasn’t resolved either.

A hormone signal that never turns off for a week and a hormone signal your body generates on its own in bursts are not the same input, even if both produce a pulse pattern on a graph. Ionescu and Frohman showed the pituitary doesn’t go flat under CJC-1295. It keeps pulsing. That’s real, and it mattered enough to settle a genuine safety question at the time. But how big those pulses are, how often they land, and what your muscle and bone actually do in response to a pattern generated by a molecule that won’t leave your bloodstream for eight days, none of that has ever been measured against what your body does on its own. Not once. Not in a human being, not across weeks of real exposure.

The pulse-preserved finding tells you the shape survived. It doesn’t tell you the shape does the same job.

What that means in plain terms: the chemical tag that solved the once-a-week problem also created a physiology question that has simply never been tested. Those aren’t two separate issues. They’re the same issue wearing two different hats. Before CJC-1295 existed, there was no such thing as a week-long, albumin-bound GHRH signal in a human body. There’s no natural version of it to compare against. The 2006 studies proved the molecule raises GH and keeps a pulse pattern intact. They never asked, and so never answered, whether that pattern produces the same result in muscle, bone, or the IGF-1 signal at the tissue level, as the pulses your body runs when nothing artificial is involved.

Nobody has answered that. Not then. Not now.

Watching your IGF-1 number climb on a lab panel doesn’t answer it either. That number tells you the molecule is doing something to the hormone axis. It says nothing about what months of that something is doing to the tissue actually using it.

If you’re the one running CJC-1295 every week, for muscle, for recovery, for whatever version of longevity you’re chasing, here’s the honest version of what you’re standing on: a single absorption-and-clearance study from 2006, and eighteen years of clinicians inferring the rest. Your GH and IGF-1 numbers going up confirm the molecule is active. They don’t confirm what that activity is building, or costing, over the months you’re actually taking it for.

Stacking it with ipamorelin, a peptide that signals GH release through a separate pathway, doesn’t close that gap either. There’s mouse data suggesting the combination helps muscle strength in specific injury models (C8), but there is no human trial testing the combination, no functional human data of any kind, and adding a second hormone-release trigger doesn’t make the original pulse-pattern question any easier to answer.

What it would actually take to close this

The gap isn’t vague. It’s a specific, buildable list.

First: a human trial that measures something real, body composition tracked with precise imaging, recovery markers, tissue-level hormone response, over at least twelve weeks of weekly dosing. Not another study of how fast the body absorbs and clears the compound. An outcome study.

Second: something to compare it against. You’d need to know whether the pulse pattern under CJC-1295 produces the same downstream effect as your body’s own bursts, which means a comparison arm, either matched subjects with normal physiology, or a short-acting version of the hormone dosed to mimic the body’s natural rhythm, tested with the same outcome measures.

Third: an honest account of what months of elevated IGF-1 does. Not confirmed dangerous. Also not confirmed safe. Unstudied is the accurate word, and treating unstudied as if it means either of the other two is where the argument gets sloppy in both directions.

None of that is expensive by pharmaceutical-trial standards. It’s expensive by the standard of a peptide nobody can patent, that’s already selling, where the adoption curve has already made the trial unnecessary from a business standpoint. The molecule doesn’t need the study to keep moving. That’s the actual reason the study hasn’t happened. Not a regulatory wall. Not a scientific impossibility. The market got there first, and once it did, nobody had a reason to go back and check.

Where this leaves it

The chemical tag that stretched CJC-1295’s half-life to a week is genuinely clever engineering, a molecule built to grab onto a blood protein and just stay there. The 2006 absorption and clearance data are clean. The pulse-preserved finding is a real result, not a marketing gloss. The molecule raises GH. It raises IGF-1. It does the job it was built to do.

But the convenience problem and the evidence problem were always the same problem wearing different clothes, and only the convenience half got solved.

CJC-1295 has been running in clinics, and in people’s own kitchen-counter protocols, for eighteen years on two papers, both published within months of each other in 2006, one mapping how fast the body absorbs and clears the compound, the other tracing the mechanism. The question those two papers left open is the same one nobody has since built a trial to answer: does a week-long, albumin-bound hormone signal produce the same result in a person’s muscle and bone as the signal their own pituitary makes when left alone?

The answer might be yes. It might even be yes in a way that matters. But that result, tested in humans, across months, at the outcomes people are actually chasing, doesn’t exist yet. Nobody has produced it.

The convenience is real. So is the gap. And right now, anyone running CJC-1295 weekly is holding both of those facts in the same vial.

If questions like this, what the evidence actually supports versus what the adoption curve assumes, are the kind of thing you want mapped before you commit to a protocol, that’s the problem Wolverine Health is built to work on.